Home Sectors Consumer Cyclical Stock in the Spotlight: Monarch Casino And Resort (NASDAQ: MCRI)

Stock in the Spotlight: Monarch Casino And Resort (NASDAQ: MCRI)

12
0
SHARE

Monarch Casino And Resort is part of the consumer cyclical sector and is part of the travel and leisure industry. The company CEO is John Farahi. Monarch Casino and Resort Inc owns and operates the Atlantis Casino Resort Spa, a hotel or casino facility in Reno, Nevada; the Monarch Casino Black Hawk in Black Hawk, Colorado and real estate proximate to the Atlantis and Monarch Casino Black Hawk.

Previous Intraday Trading Performance:

The MCRI stock showed a previous change of -0.12% with an open at 40.24 and a close of 40.35. It reached an intraday high of 41.63 and a low of 40.15.

SeekingAlpha:  Monarch Casino & Resort beats by $0.01, misses on revenue

Liquidity:

The stock has a market cap of $722.0m with 17.9m shares outstanding, of which the float is 14.5m shares. Trading volume reached 28,855 shares compared to its average volume of 56,354 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Monarch Casino And Resort shares returned -0.27% and in the past 30 trading days it returned -11.22%. Over three months, it changed -14.75%. In one year it has changed -12.63% and within that year its 52-week high was 49.63 and its 52-week low was 37.33. MCRI stock is 8.09% above its 52 Week Low.

Our calculations show a 200 day moving average of 44.53 and a 50 day moving average of 44.09. Currently MCRI stock is trading -9.39% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Monarch Casino & Resort beats by $0.01, misses on revenue

Earnings:

The last annual fiscal EPS for the company was reported at 1.39 that ended on 31st of December 2017, which according to the previous close, that is a PE of 29.03. Based on 2 analyst estimates, the consensus EPS for the next quarter is 0.57. The TTM EPS is 1.75, which comes to a TTM PE of 23.06. Historically, the PE high was 38.50 and the PE low was 10.60. If the stock reached its PE low, that would represent a price of 18.55, which is a decrease of -54.03%.

The following are the last four quarter reported earnings per share:
09-30-2018:  0.58
06-30-2018:  0.50
03-31-2018:  0.36
12-31-2017:  0.31

Base on our calculations, the intrinsic value per share is 65.01, which means it is possibly undervalued and has a margin of safety of 37.94%

Indicators to Watch:

Based on the latest filings, there is 41.30% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.28

SeekingAlpha:  Momenta Pharmaceuticals misses by $0.10, misses on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 10.98%, return on assets is 8.22%, profit margin is 12.74%, price-to-sales is 2.98 and price-to-book is 2.58.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 2  :Past Performance Score
 4  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.